Multiple Myeloma
Also known as: Myeloma, Plasma Cell Myeloma, Kahler Disease
Multiple myeloma is a cancer of plasma cells — white blood cells that produce antibodies — in the bone marrow. Abnormal plasma cells multiply uncontrollably, producing abnormal proteins (M proteins) that can damage bones, kidneys, and the immune system. It is the second most common blood cancer in the United States, and while there is no cure, modern treatments have significantly extended survival.
Last updated November 10, 2026
Understanding Multiple Myeloma
Multiple myeloma is a cancer of plasma cells, the antibody-making white cells that live in the bone marrow. A single abnormal plasma cell clone multiplies, crowds out normal blood production and pours out one useless antibody fragment, the M protein, that shows up on blood and urine tests. It accounts for about 1 to 2 percent of all cancers and roughly 10 percent of blood cancers: the American Cancer Society expects around 36,000 new US diagnoses and about 12,500 deaths in 2025. The median age at diagnosis is 69, fewer than 1 in 20 cases occur under 50, men are affected slightly more often than women, and Black Americans develop it at about twice the rate of white Americans and several years younger. Almost every case is preceded by a silent precursor state, MGUS, which is present in about 3 percent of people over 50 and progresses at roughly 1 percent per year.
The damage comes from three directions. The expanding clone crowds the marrow, so hemoglobin falls and fatigue is often the first symptom. Myeloma cells signal nearby bone cells to dissolve bone faster than it is rebuilt, producing the punched-out lesions, fractures and high calcium behind the classic back pain; about 80 percent of people have bone disease at diagnosis. And the M protein, or more often its free light chain fragments, clogs and poisons the kidney tubules, so 20 to 40 percent arrive with reduced kidney function and 2 to 5 percent need dialysis. Normal antibody production collapses at the same time, which is why pneumonia and other infections are the leading cause of death in the first months after diagnosis. The usual sequence is MGUS, then smoldering myeloma with 10 percent or more marrow plasma cells but no organ damage, then active disease defined by the CRAB features or by the 2014 International Myeloma Working Group biomarkers (60 percent or more plasma cells, a light chain ratio of 100 or more, or more than one focal lesion on MRI).
Treatment is sequenced rather than one-off, and the National Comprehensive Cancer Network and International Myeloma Working Group guidelines now start nearly everyone on a three or four drug combination. For people fit enough, induction with daratumumab, bortezomib, lenalidomide and dexamethasone followed by an autologous stem cell transplant is standard: in the PERSEUS trial (709 patients, 2024), adding daratumumab raised 4-year progression-free survival from 67.7 to 84.3 percent, and the DETERMINATION trial (722 patients, 2022) showed transplant lengthens median progression-free survival from 46 to 67.5 months. For those who cannot have a transplant, daratumumab plus lenalidomide and dexamethasone in the MAIA trial (737 patients) produced a median progression-free survival above 5 years. Relapsed disease now has CAR T-cell therapy and bispecific antibodies, with response rates of 60 to 98 percent in heavily pretreated patients. Alongside all of this, monthly zoledronic acid or denosumab cuts fractures, and in the MRC Myeloma IX trial of 1,970 patients zoledronic acid lengthened survival by 5.5 months. Five-year relative survival has climbed to about 60 percent, and many people now live well beyond 10 years.
No supplement, herb, diet or infusion treats myeloma, slows it or substitutes for any of the drugs above, and this page will not pretend otherwise. The useful role of supplements is narrow and supportive: correcting vitamin D deficiency, which affects 40 to 60 percent of people at diagnosis and is required alongside bisphosphonates or denosumab to prevent dangerous drops in calcium; replacing vitamin B12 when it is low; and, for people with MGUS or smoldering disease who are only being watched, curcumin has small trials showing modest falls in paraprotein and light chains that have never been shown to prevent progression. Some popular products are actively harmful during treatment. Green tea extract (EGCG) binds and inactivates bortezomib in laboratory and animal studies, and high-dose vitamin C does the same, so both should be avoided while on bortezomib or ixazomib. St John's wort induces the liver enzymes that clear bortezomib and dexamethasone. Probiotic capsules have caused bloodstream infections in people with low neutrophil counts. Alkaline diets, intravenous vitamin C, apricot kernels and anti-cancer mushroom extracts have no evidence in myeloma.
The most common mistake is treating supplements as private business. Myeloma drugs have narrow margins, and a hematologist cannot interpret a surprising lab result or a weak response if they do not know about the curcumin, the green tea capsules or the vitamin C infusions. Bring every bottle to appointments, and expect to be asked to stop most of them around transplant. The second mistake is waiting for bone pain to become severe before mentioning it: new back pain in myeloma can mean a vertebral fracture or early spinal cord compression, and weakness, numbness or trouble controlling bladder or bowel is an emergency that needs same-day imaging. A temperature of 38 C (100.4 F) or higher during treatment is likewise an emergency, not something to sleep on, because infections in myeloma move fast. Finally, keep up with vaccines: inactivated flu, pneumococcal, COVID-19 and the recombinant shingles vaccine are all recommended, while live vaccines are not.
At a Glance
- Common symptoms
- Bone pain, especially in the spine, ribs, and hips, Fatigue from anemia, Frequent infections due to impaired immunity
- Main treatments
- Combination chemotherapy with proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory drugs (lenalidomide, pomalidomide), and dexamethasone, Autologous stem cell transplant for eligible patients, Monoclonal antibodies (daratumumab, elotuzumab)
- Category
- Cancer · About 35,000 new cases per year in the US
- See a doctor if
- Persistent unexplained bone pain, especially in the back or ribs
Symptoms
Causes
- Malignant transformation of plasma cells in the bone marrow
- Chromosomal abnormalities and gene mutations
- Often preceded by monoclonal gammopathy of undetermined significance (MGUS)
Risk Factors
- Age over 65 (median age at diagnosis is 69)
- Male sex (slightly more common in men)
- African American descent (twice the incidence of Caucasians)
- Family history of myeloma or MGUS
- History of MGUS or smoldering myeloma
- Obesity
Diagnosis
- Serum and urine protein electrophoresis (SPEP/UPEP) and immunofixation
- Serum free light chain assay
- Bone marrow biopsy showing ≥10% clonal plasma cells
- Skeletal survey, PET/CT, or low-dose whole-body CT for bone lesions
- Blood tests: CBC, creatinine, calcium, beta-2 microglobulin, LDH, albumin
Treatment
- Combination chemotherapy with proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory drugs (lenalidomide, pomalidomide), and dexamethasone
- Autologous stem cell transplant for eligible patients
- Monoclonal antibodies (daratumumab, elotuzumab)
- CAR T-cell therapy (idecabtagene vicleucel, ciltacabtagene autoleucel) for relapsed disease
- Bispecific antibodies (teclistamab, elranatamab)
- Supportive care: bisphosphonates for bone disease, erythropoietin for anemia
Natural remedies for multiple myeloma: what the evidence says
Ranked by the strength of human evidence for multiple myeloma specifically. These sit alongside medical care, not in place of it.
Vitamin D
Moderate evidenceLow vitamin D is found in 40 to 60 percent of people with newly diagnosed myeloma and, in a Mayo Clinic series of 148 patients, was associated with higher-stage disease, higher CRP and worse kidney function, though no trial shows that correcting it changes survival. What is established is that calcium and vitamin D are needed with zoledronic acid and denosumab, which otherwise cause symptomatic hypocalcemia in up to 1 in 10 people; the denosumab trials supplemented everyone. Correcting deficiency also supports bone and muscle during long steroid courses.
- Studied dose
- 1,000 to 2,000 IU vitamin D3 daily, adjusted to keep 25-hydroxyvitamin D above 30 ng/mL; repletion of severe deficiency is done under supervision.
- Cautions
- Do not take calcium or high-dose vitamin D if your calcium is high, which is common in untreated myeloma; your team will tell you when it is safe. Check a vitamin D level rather than guessing, and tell your team, because doses interact with kidney function and bisphosphonate timing.
Curcumin
Preliminary evidenceIn a 2009 crossover study of 26 people with MGUS, 4 g of curcumin daily lowered paraprotein by 12 to 30 percent in 5 of the 10 with higher starting levels. A 2012 placebo-controlled crossover trial in 36 people with MGUS or smoldering myeloma found 4 g daily, then 8 g open-label, reduced the free light chain ratio and a marker of bone turnover (urinary N-telopeptide) in a proportion of participants over 3 to 9 months. No trial has shown curcumin delays progression to active myeloma or helps during treatment, so this is a watch-and-wait experiment to discuss with your hematologist, not a treatment.
- Studied dose
- 4 g daily of a standard curcumin extract (C3 complex with piperine) was used in the trials; 8 g was tolerated but caused more stomach upset.
- Cautions
- Curcumin has antiplatelet effects and can add to bleeding risk when platelets are low or with anticoagulants, and piperine-containing products raise levels of many drugs. Avoid with gallstones, stop 2 weeks before transplant or surgery, and never start it during active treatment without telling your team, because its effects on bortezomib and other agents have not been tested in people.
Vitamin B12
Preliminary evidenceA Cleveland Clinic study of people with plasma cell disorders found vitamin B12 deficiency in roughly 1 in 7 with active myeloma, several times the rate in MGUS, probably from gut changes, metformin, acid suppression and reduced intake. Low B12 worsens the anemia and fatigue myeloma already causes and adds to the peripheral neuropathy that bortezomib and thalidomide produce. Replacing a documented deficiency improves hemoglobin and nerve symptoms; taking B12 without a low level has no demonstrated benefit.
- Studied dose
- 1,000 mcg oral cyanocobalamin or methylcobalamin daily, or injections if absorption is poor, until levels normalize.
- Cautions
- Safe; ask for a vitamin B12 level with methylmalonic acid before starting, because folic acid alone can mask B12 deficiency. The paraprotein has been reported to interfere with B12 assays, so an odd result should be repeated rather than acted on.
Omega-3
Preliminary evidenceThere is no trial of fish oil in myeloma itself. The relevant evidence is for cancer-related weight loss, where about 2 g a day of EPA preserved weight and muscle in some trials of advanced cancer (for example 200 people with pancreatic cancer in 2003), and for chemotherapy nerve damage, where a 12-week trial in about 60 women on paclitaxel found 640 mg of omega-3 three times daily cut neuropathy incidence from 59 to 30 percent. Whether this applies to bortezomib neuropathy is unknown.
- Studied dose
- 1 to 2 g combined EPA and DHA daily with food, from a product tested for oxidation.
- Cautions
- Mild antiplatelet effect, so discuss with your team if platelets are low or you take anticoagulants, and stop a week before transplant or surgery. Fishy burps and loose stools are common; use with care in atrial fibrillation, which doses above 2 g may provoke.
What matters day to day
- Treat a temperature of 38 C (100.4 F) or higher as a same-day call, any hour: infection is the leading cause of early death in myeloma, and treatment lowers neutrophil counts, so the window for antibiotics is hours, not days.
- Drink 2 to 3 liters of fluid a day unless told otherwise and avoid ibuprofen, naproxen and other NSAIDs: free light chains damage kidney tubules, and dehydration or NSAIDs can tip 20 to 40 percent who start with reduced kidney function into failure.
- Keep moving with a physiotherapist-guided program of walking and light resistance work: exercise reduces myeloma fatigue in trials, but bone lesions mean no heavy lifting, twisting or high-impact sport until your team clears it.
- See a dentist before starting zoledronic acid or denosumab and finish any extractions first: osteonecrosis of the jaw occurs in about 1 to 3 percent of myeloma patients on long-term bone agents, mostly after dental surgery.
- Know the clot signs if you take lenalidomide, thalidomide or pomalidomide with dexamethasone: without prophylaxis 10 to 20 percent develop a venous clot, so take the aspirin or anticoagulant prescribed and report calf swelling, chest pain or breathlessness immediately.
- Get the recommended vaccines and skip live ones: yearly inactivated flu, pneumococcal, COVID-19 and the two-dose recombinant shingles vaccine, which was 90 percent effective in immunocompromised adults; live vaccines are unsafe during treatment.
Prevention
- No known prevention for multiple myeloma
- Monitoring of MGUS patients for progression (annual blood tests)
When to See a Doctor
- Persistent unexplained bone pain, especially in the back or ribs
- Unexplained anemia or fatigue
- Recurrent infections
- Elevated protein or calcium found on routine blood tests
Frequently Asked Questions
References
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology (2014)
- Sonneveld P, Dimopoulos MA, Boccadoro M, et al.. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma (PERSEUS). New England Journal of Medicine (2024)
- Richardson PG, Jacobus SJ, Weller EA, et al.. Triplet therapy, transplantation, and maintenance until progression in myeloma (DETERMINATION). New England Journal of Medicine (2022)
- Facon T, Kumar SK, Plesner T, et al.. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncology (2021)
- Morgan GJ, Davies FE, Gregory WM, et al.. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet (2010)
- Golden EB, Lam PY, Kardosh A, et al.. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood (2009)
- Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. American Journal of Hematology (2012)
- Ng AC, Kumar SK, Rajkumar SV, Drake MT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. American Journal of Hematology (2009)
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma (2025)
- MedlinePlus, National Library of Medicine. Multiple Myeloma (2024)View source
Related Conditions
Lab tests that relate to multiple myeloma
Have questions about Multiple Myeloma?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.